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Available online 18 May 2016We describe here a lateral ﬂow-based assay (LFA) for the detection of antibodies against immunodominant an-
tigen Pgp3 from Chlamydia trachomatis, the causative agent of urogenital chlamydia infection and ocular tracho-
ma. Optimal signal detectionwas achievedwhen the gold-conjugate and test line contained Pgp3, creating a dual
sandwich capture assay. The LFA yielded positive signals with serum and whole blood but not with eluted dried
blood spots. For serum, the agreement of the LFAwith the non-referencemultiplex assay was 96%, the speciﬁcity
using nonendemic pediatric sera was 100%, and the inter-rater agreement was κ= 0.961. For whole blood, the
agreement of LFA with multiplex was 81.5%, the speciﬁcity was 100%, and the inter-rater agreement was κ =
0.940. The LFA was tested in a ﬁeld environment and yielded similar results to those from laboratory-based test-
ing. These data show the successful development of a lateral ﬂow assay for detection of antibodies against Pgp3
with reliable use in ﬁeld settings, which would make antibody-based testing for trachoma surveillance highly
practical, especially after cessation of trachoma elimination programs.ss article under the CC BY license (htPublished by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Lateral ﬂow1. Introduction
Trachoma, resulting from repeated infection with the bacterium
Chlamydia trachomatis (Ct), is the leading global infectious cause of
blindness. Blinding trachoma as a public health problem is targeted for
elimination by 2020 using the SAFE strategy: Surgery for trichiasis, An-
tibiotics to treat infection, Facial cleanliness to prevent spread of infec-
tion, and Environmental improvement. Antibiotic distribution
(Zithromax™, donated by Pﬁzer) is carried out through annual mass
drug administration (MDA) (Solomon et al., 2006). Current decision-
making for starting and stoppingMDA programs are based on the prev-
alence of the clinical indicator trachomatous inﬂammation–follicular
(TF) among 1–9 year olds. An impact assessment is conducted after 1,
3, 5, or 7 rounds of MDA, depending on the baseline TF level, and MDA
is stopped if the district-wide prevalence of TF is b5%. Two years after
stopping MDA, a survey is done to show continued TF levels b5%,
which will provide the evidence for a dossier for validation of elimina-
tion of trachoma as a public health problem (“pre-validation survey”).
However, in post-MDA settings where trachoma prevalence is low,
the correlation between TF and active ocular infection breaks down
(Mabey et al., 2003; Burton et al., 2011), in part because otherpathogens can cause similar clinical signs (Dean et al., 2008; Capriotti
et al., 2009; Dean et al., 2013).
The program end point for trachoma does not require complete
elimination of the bacterium causing trachoma. Therefore, a sensitive
and speciﬁc measure of Ct exposure will be critical at the end of pro-
grams and in post-validation settings for trachoma surveillance to en-
sure lack of recrudescence of infection. We have recently shown that
antibody responses against Ct antigens Pgp3 and CT694 show high sen-
sitivity and speciﬁcity for ocular Ct infection (Goodhew et al., 2012),
suggesting antibodies are good markers of exposure to Ct. Antibody re-
sponses appear to be long-lived and act as indicators of historical rather
than active infection (Goodhew et al., 2014). Analysis of antibody re-
sponses fromyoung children born after cessation ofMDAshows that se-
roprevalence represents a good indicator of low to no transmission
(Martin et al., 2015a; Pant et al., 2016;West et al., 2016). Initial serolog-
ical studies used multiplex bead array (MBA) testing, which is highly
sensitive and can be integrated with other serological tests. However
this technology is not feasible for many trachoma-endemic countries
due to the high initial cost of the instrumentation and the need tomain-
tain high technical capacity and strong infrastructure for analysis and
maintenance of the instrument. We therefore sought to develop a
ﬁeld-deployable lateralﬂow-based assay formeasuring anti-Ct antibod-
ies and chose Pgp3 based on the large amount of data on this protein as
an immunodominant Ct antigen (Comanducci et al., 1994;
Ghaem-Maghami et al., 2003; Li et al., 2008; Wills et al., 2009).tp://creativecommons.org/licenses/by/4.0/).
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2.1. Samples
Serum samples were collected from a community in Nepal in 2000,
2002, or 2014 as part of a study of trachoma post-MDA serosurveillance
(N= 432; age range 1–90 Gwyn et al., manuscript in preparation) that
had been tested on a previously-described multiplex bead array (MBA)
assay for antibodies against the Ct antigen Pgp3 (Goodhew et al., 2012,
2014; Martin et al., 2015b). Two extensively studied Pgp3-positive con-
trol samples from Haiti were used for test optimization. For speciﬁcity
testing, a set of serum samples from 4 to 9 year olds from three commu-
nities in central Bolivia collected as part of a study of Chagas disease in
2010 were used as non-trachoma endemic controls (N = 78). Whole
blood specimens (N= 301) from a subset of the Nepal serum samples
described above were manufactured by spiking an equal volume of
study serum into red blood cells depleted of plasma from negative con-
trol blood (Mei et al., 2001). For testing of dried blood spots, serumwas
eluted from dried blood spots from 1 to 9 year olds in Tanzania as pre-
viously described (Goodhew et al., 2012). Samples were collected
under protocols approved by local IRBs, and CDC staff were determined
to be not engaged in the research study by the CDC human subjects
coordinator.
2.2. Antigen preparation
Methods for selection and isolation of the Ct antigen Pgp3 have been
previously described (Goodhew et al., 2012).
2.3. Optimization of lateral ﬂow conditions
The optimal conditions for the LFA were determined using the “wet
test”. Brieﬂy, nitrocellulosemembraneswere dipped intowells contain-
ing assay buffer, positive and negative control serum, and conjugate.
Conditions that yielded the strongest test-line signal, when tested
with positive control samples and no test-line signal when tested with
negative control samples, were chosen. Conjugate reagents tested
were: anti-human IgG colloidal gold, protein A-colloidal gold and
Pgp3-colloidal gold. Todetermine the optimal conditions for the capture
reagent, recombinant Pgp3 was dispensed onto a nitrocellulose mem-
brane at various concentrations: 2.0 mg/mL, 1.75 mg/mL, 1.50 mg/mL,
1.25 mg/mL and 1.00 mg/mL.
2.4. Preparation of lateral ﬂow assay
Conjugate reagents and capture reagents were prepared with opti-
mal conditions. For the capture reagents, Pgp3 protein (1.5 mg/mL)
and biotinylated bovine serum albumin (BSA-biotin, 1.5 mg/mL; Arista
Biologicals, Allentown, PA, USA) were dispensed onto the test and con-
trol lines, respectively, of a nitrocellulose membrane (Millipore, Billeri-
ca, MA) at a rate of 0.1 μL/mm using an IsoFlow Dispenser (Imagene
Technology, Hannover, NH). The detection reagent (conjugate) was
prepared by conjugating Pgp3 to InnovaCoat Gold (Innova Biosciences,
Cambridge, UK) following the manufacturer's instructions. The conju-
gate pad was treated with a buffer containing 20 mM phosphate-buff-
ered saline (PBS) pH 7.4, 2% BSA, 2.5% sucrose, 0.3%
polyvinylpyrrolidone, 1% Tween-20 and dried overnight at room tem-
perature. Pgp3-gold conjugate and streptavidin-gold (SA-gold) conju-
gate (Arista Biologicals) were washed and suspended in buffer
containing 2 mM borate pH 7.4, 5% sucrose and 5% trehalose. Pgp3-
gold and SA-gold conjugates were mixed at a 4:1 ratio and sprayed
onto the pre-treated conjugate pad at a rate of 0.6 μL/mm using the
IsoFlow Dispenser. The blood separation membrane (Lydall, Manches-
ter, CT) was treated with a buffer containing 10 mM PBS pH 7.4, 5%
BSA, 0.05% Tween and dried at room temperature overnight.2.5. Assembly of lateral ﬂow assay device
An absorbent pad (Arista Biologicals), nitrocellulose membrane,
conjugate pad, blood separation membrane, and buffer pad (Millipore)
were placed on a backing card (DCNDiagnostics, Carlsbad, CA)with a 1–
2mm overlap between each material to facilitate sample ﬂow. A guillo-
tine cutter (Arista Biologicals) was used to produce 4.5 mm strips,
which were then placed in plastic housing (DCN Diagnostics). All LFA
cassettes were stored at room temperature in a desiccator cabinet
with a relative humidity of b15%.2.6. LFA protocol
Serum (10 μL) or whole blood (20 μL) was applied to the sample ap-
plicator port, followed by 200 μL of chase buffer (10 mM PBS, 0.3%
Tween 20) added to the buffer applicator port, forcing samplemigration
onto the conjugate pad. Antibodies speciﬁc for Pgp3 present in the sam-
ple bind to the Pgp3-gold conjugate and continue to travel up the nitro-
cellulose membrane. Anti-Pgp3 antibodies bound to the Pgp3-gold
conjugate then bind to Pgp3 present on the test line, producing a visible
test line signal by accumulation of gold particles on the test line. SA-gold
conjugate bound to BSA-biotin on the control line produces a signal ir-
respective of the presence of anti-Pgp3 antibodies in the sample. Excess
liquid is absorbed by the absorbent pad (Fig. 1).
A test was considered valid only if it produced a signal on the control
line. Testswere scored as either positivewhen a clear test linewas pres-
ent (recorded as + or ++ depending on the intensity of the line), or
negative when no test line (−) or a faint but difﬁcult to distinguish
test line (±) was observed. Samples that received a positive score by
one user and a negative score by the other user were categorized as
“inconclusive”.2.7. Field comparison to laboratory testing
A set of 200 serum samples previously tested by LFA in the CDC lab-
oratory was shipped to the Kongwa Trachoma Project in Kongwa, Tan-
zania, where trachoma is endemic. Lateral ﬂow assays were
transported at ambient temperatures to Tanzania in foil pouches (DCN
Diagnostics) containing desiccant, and were stored at ambient temper-
atures for 5–8 days prior to use.2.8. Statistical analysis
The agreement of the LFAwith the Pgp3MBAwas determined as the
percentage of LFA-positive of the number of positive samples by MBA.
Speciﬁcity of the assay was determined against a group of serum sam-
ples from children from non-trachoma endemic settings. Inter-rater
agreement was calculated using Cohen's kappa coefﬁcient with
GraphPad Prism.3. Results
3.1. Optimization of LFA
Optimization of Pgp3 concentration on the test line and capture re-
agents conjugated to colloidal gold using positive controls showed the
strongest test line signal with the combination of Pgp3-colloidal gold
and 1.5 mg/mL of Pgp3 as the capture reagent (Fig. 1). Representative
positive and negative tests are shown in Fig. 2. Time courses were run
on each new lot of LFAs using negative, high positive, and low positive
control sera. The optimal read time based on a time course of 15, 20,
30, 60, and 120 min was 30 or 60 min; 30 min was chosen for initial
testing.
Fig. 1. Schematic of Pgp3 lateral ﬂow assay.
Fig. 2. LFA test. Shown are results of the LFA run with positive (left) and negative (right)
control sera.
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Serum(N=512)was tested on the LFA for anti-Pgp3 antibodies and
read by two independent graders.
The agreement of LFA with MBA-positive samples was 96% and the
speciﬁcity was 100% (Table 1). Inter-rater agreement was very good,
with a Cohen's kappa coefﬁcient of 0.961 (95% CI 0.937–0.985, data
not shown).
3.3. Performance of LFA with whole blood
The agreement of LFAwithMBA-positive sampleswas 81.3% and the
speciﬁcity was 100% (Table 1). Inter-rater agreement (κ) was 0.940
(95% CI 0.900–0.981). Out of 301 paired whole blood and serum sam-
ples, 94 (31.3%) were both scored as positive, 174 (57.8%) were both
scored as negative, 14 (4.6%)were scored as inconclusivewith one sam-
ple type and 19 (6.3%)were scored as positivewith one sample type but
negative with the other (Table 2). The complete set of readings for all
samples by each user for serum and whole blood is shown in Supple-
mentary Table 1.
3.4. Field performance of LFA
The agreement of LFA with Pgp3-positive samples by MBA was 92%
when tested with serum at a ﬁeld site in Tanzania (Table 1). Inter-rater
agreementwas 0.890 (95% CI 0.827–0.953). Out of 200 samples evaluat-
ed by two readers each in both the laboratory and the ﬁeld, 173 (86.5%)
were graded the same in both sites (89 [44.5%] were scored as positive
at both sites and 84 [42%] were scored as negative) (Table 3). Seventeen
(8.5%)were scored as inconclusive at one site but either positive or neg-
ative at the other (Table 3). Ten (5%) were scored as positive at one site
but negative at another site (Table 3). Ratings by each user in the labo-
ratory and in the ﬁeld is shown in Supplementary Table 1.
3.5. Stability of test line
Tests run in the ﬁeld were shipped back to CDC and read again
4 months later. Agreement between readings were good (κ = 0.728,
CI 0.640–0.816). The majority of positives at the original 30 min read
being called positive 4 months later (87/89, 97.7%, Table 4). Of the 78
Table 1
Speciﬁcity of the lateral ﬂow assay (LFA) and agreement with multiplex bead array (MBA) testing. Serum specimens were run on the MBA and LFA. Samples were run on LFA in a labo-
ratory at CDC (“Lab”, N=322) or at Kongwa Trachoma Project (“Field”, N=93). A subset of serum sampleswere added to plasma-depleted bloods cells (“Whole Blood”, N=190). n.d.=
not done. 95% conﬁdence intervals (CI) are shown in brackets.
Sample type LFA result MBA-positives (percent [95% CI]) Non-endemic children (percent [95% CI])
Serum (lab) Positive 235 (96.3)
[93.9–98.7]
0
Inconclusive 4 (1.6)
[0–3.2]
0
Negative 5 (2.0)
[0.24–3.8]
78 (100)
[100−100]
Total 244 78
Whole blood Positive 91 (81.3)
[74.1–88.5]
0
Inconclusive 7 (6.2)
[1.7–10.7]
0
Negative 14 (12.5)
[6.4–18.6]
78 (100)
[100–100]
Total 112 78
Serum (ﬁeld) Positive 85 (91.4)
[85.7–97.1]
n.d.
Inconclusive 3 (3.2)
[0–6.8]
n.d.
Negative 5 (5.4)
[0.81–10.0]
n.d.
Total 93 n.d.
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4months (Table 4).Most (13/16, 81.3%) of the specimens read as incon-
clusive at 30minwere read as positive at 4months. Eight testswere un-
able to be conﬁdently read at 4 months due to the test line being
obscured; most of these (6/8) were negative at the original 30 min
read (Table 4).
4. Discussion
We describe here a lateral ﬂow assay for detection of antibodies
against the Ct antigen Pgp3 with good agreement compared to results
from Pgp3 multiplex bead array testing and speciﬁcity against a panel
of serum samples from children from a non-endemic country. Inter-
rater agreement was also very strongwith a κ of 0.961 in the laboratory
site and 0.89 at the ﬁeld site. The LFA tests were also very stable,
performing well in dry, arid conditions in a trachoma-endemic district
of Tanzania after approximately one week at ambient temperatures.
The dual Pgp3 capture of serum antibodies in this LFA add an extra
dimension to this assay compared to the ELISA or MBA because the
LFA does not distinguish between antibody isotypes. We have shown
that IgA antibodies are also present in serum (Goodhew et al., 2014)
and IgM antibodymay also be present. This may increase the sensitivity
of the LFA by detecting the presence of multiple isotypes.
Whilewe undertook thiswork to develop a rapid antibody test for Ct
to facilitate country-based serosurveillance for trachoma, there are po-
tential applications for use of this test for urogenital infection as well.
Serologic testing provides information on past as well as current expo-
sure to Ct and, therefore provides a broader picture of population expo-
sure to Ct than active case detection for either ocular trachoma or
urogenital chlamydia. The seroepidemiology of urogenital Ct has al-
ready been evaluated in some settings (Johnson and Horner, 2008;
Lyytikainen et al., 2008; Horner et al., 2013) and a low-cost test such
as what we have presented here (currently b1.50 USD per test) mayTable 2
Comparison of performance of the LFA with serum and whole blood, N = 301 paired
specimens.
Serum positive Serum inconclusive Serum negative
Blood positive 94 1 2
Blood inconclusive 7 1 0
Blood negative 17 5 174allow this type of serosurvey for urogenital chlamydia to be feasible in
settings with limited laboratory capacity.
One drawback of the LFA is that the inter-rater agreement was
slightly lower at the ﬁeld site than in the laboratory. This may due in
part to variations in natural lighting conditions in the ﬁeld depending
on the position of the reader, such as facing a window or with the
back to a window. Using an artiﬁcial light source, such as a ﬂashlight,
to illuminate the strip in a ﬁeld setting may facilitate reading the strip
and improve inter-rater agreement. Disagreement between readers
tended to occur on samples for which the MBA values fell near the
cut-off (data not shown). However, the stability of the test line —
85.7% of negative samples at the 30 min reading were read as negative
and 97.7%of positiveswere read as positive 4months later—potentially
negates this drawback, as without the restriction of a time-sensitive
test, consensus readings can be used. There was a trend towards an in-
crease calling samples positive at the later reading. Eleven samples read
as negative at 30minwere called positive or inconclusive at 4months. It
is unclear if trend towards positive readings at 4 months is because the
test lines become more clear over time or if the reader was more likely
to call a faint line positive because of increased comfort in reading the
test at the later time point. An automated reader for lateral ﬂow tests
would be useful to address the issue of reader subjectivity for this test.
An additional limitation is the lack of a true gold standard to indicate
historical infectionwith Ct, thereby hindering determination of the sen-
sitivity of the LFA. Sensitivity of the Pgp3 MBA was determined from a
set of sera from children in endemic countries with nucleic acid ampli-
ﬁcation test (NAAT)-positive ocular swabs (Goodhew et al., 2012). For
the sensitivity determination of this LFA prototype, we are limited to a
set of serum samples that lack ocular infection data, thereby precluding
determination of sensitivity testing using the gold-standard NAAT.
Dried blood spots — the specimen type uniformly used in trachoma
studies — cannot be used with the current iteration of the test due to
high background signal. Additionally, it is important to note that NAATTable 3
Performance of the LFA in the laboratory (“Lab”) and ﬁeld setting, N = 200, matched se-
rum specimens.
Lab positive Lab inconclusive Lab negative
Field positive 89 3 3
Field inconclusive 3 0 8
Field negative 7 3 84
Table 4
Comparison of readings at 30 min (reading 1) and four months (reading 2) after sample
testing.
Reading 2
Reading 1 Pos Neg Inconclusive Unreadable
Pos 87 1 0 1
Neg 5 61 6 6
Inconclusive 13 1 1 1
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itive samples to deﬁne the sensitivity of a test for antibody is somewhat
limiting. Ocular infection will resolve even in the absence of treatment
following 2–6 weeks (Bailey et al., 1999), whereas the longevity of
anti-pgp3 responses is not currently known, although it is certainly
months (Goodhew et al., 2014) and most likely years or decades, likely
depending on the number of infections an individual incurs. As such, the
usage of antibody tests and by extension the lateral ﬂow assay present-
ed here is population-level surveillance and not diagnosis of trachoma
in an individual.
Serosurveillance for trachoma following validation of elimination of
trachomawill be critical since the endpoint for trachomaprogram is the
elimination of blinding trachoma as a public health problem and not the
interruption of transmission of ocular Ct infection. There therefore re-
mains a chance of recrudescence of disease. Funding for post-elimina-
tion surveillance is virtually nonexistent, so the ability to integrate
trachoma surveillance with ongoing public health surveys will be cru-
cial, having low-cost tools that require little-to-no technical expertise
and can use blood specimens potentially collected for other purposes
will be the most practical way to accomplish post-validation surveil-
lance of trachoma.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jim.2016.05.008.
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